InfaCare is an emerging specialty pharmaceutical company focused on the development and commercialization of proprietary pharmaceuticals for the neonatal and pediatric patient population. InfaCare was founded in 2005, is staffed by seasoned pharmaceutical executives who bring extensive experience of global drug development and commercialization both within large pharmaceutical companies and virtually integrated start up biotech environments. The board of directors includes pharmaceutical executives and investors from top tier venture capital companies. InfaCare’s lead product, Stanate®, is the only pharmacologic treatment for infantile jaundice, or hyperbilirubinemia (“HB”) currently in development. InfaCare has worked with prominent drug manufacturers to produce pharmaceutical grade (GMP) processes and product, and with contract research organizations to conduct necessary preclinical and clinical studies on Stanate®. At present the Company is conducting a multicenter phase 2B clinical study of Stanate in neonates which is expected to complete in 2014.
InfaCare has global rights to Stanate including an extensive patent estate.
Investor enquiries should be addressed to: